SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma reports 75% fall in Q4 consolidated net profit

25 May 2023 Evaluate

Piramal Pharma has reported results for fourth quarter (Q4) and year ended March 31, 2023.

The company has reported 72.46% fall in its net profit at Rs 41.70 crore for the quarter under review as compared to Rs 151.44 crore for the same quarter in the previous year. Total income of the company decreased by 7.06% at Rs 1,117.46 crore for Q4FY23 as compared to Rs 1,202.38 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 75.44% fall in its net profit at Rs 50.11 crore for fourth quarter ended March 31, 2023 as compared to Rs 204.06 crore for the same quarter in the previous year. Total income of the company decreased by 0.97% at Rs 2,188.08 crore for Q4FY23 as compared to Rs 2,209.50 crore for the corresponding quarter previous year.

For the year ended March 31, 2023, the company has reported 81.09% fall in its net profit at Rs 69.50 crore as compared to Rs 367.54 crore for the previous year. However, total income of the company increased by 6.14% at Rs 3784.29 crore for year under review as compared to Rs 3,565.21 crore for year ended March 31, 2022.

For the year ended March 31, 2023, on the consolidated basis, the company has reported net loss of Rs 186.46 crore as compared to net profit of Rs 375.96 crore for the previous year. However, total income of the company increased by 6.90% at Rs 7,306.66 crore for year under review as compared to Rs 6,834.90 crore for year ended March 31, 2022.

Piramal Pharma Share Price

148.90 1.45 (0.98%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×